HOME >> BIOLOGY >> NEWS
JCI table of contents, 16 August, 2004

Putting Energy into Heart Protection

Under conditions of stress, molecular mechanisms stop cells from consuming their source of energy, ATP, and trigger them to begin to produce ATP. This is done by inducing cells to stop any biochemical pathways that use energy and by turning on processes that take up glucose and free fatty acids from their surroundings in order to rebuild their ATP reservoir. The main protein involved in this switch is called AMP-activated protein kinase (AMPK). One situation of obvious energy stress on cells is during a heart attack. Lawrence Young and colleagues at Yale University School of Medicine, have now investigated the biological importance of AMPK during heart trauma in mice, and find that AMPK is vital for protecting cells under conditions of a heart attack. The authors used a transgenic mouse that had an inactivated AMPK and found that under normal circumstances the hearts of these mice and those of wild-type mice were generally similar in form and function. These mutant mice did have slightly lower diastolic pressure in the left ventricle. Upon reduction of blood flow to the heart, to simulate a heart attack, they found that the mice without a functioning AMPK could not stimulate glucose uptake, although the molecular mechanisms for glucose uptake were intact, nor did they breakdown fatty acids to replenish ATP. Once blood flow returned, contractile function in the left ventricle of the mutant mice was impaired. The authors found that there was an increased amount of cell death in these tissues, both through necrosis and programmed cell death, called apoptosis. These data indicate that AMPK is responsible for altering cellular mechanisms for energy in the heart and plays an important protective role during and after a heart attack. The identification of novel AMPK targets and/or the possible use of AMPK activators may be useful in providing therapy for healing during or after a heart attack.

A related c
'"/>

Contact: Laurie Goodman
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
16-Aug-2004


Page: 1 2 3 4 5 6 7 8 9 10

Related biology news :

1. Chemical engineering grad students will take notable national awards
2. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
3. JCI table of contents September 15, 2004
4. JCI table of contents: 1 September, 2004
5. Anti-cancer compound in vegetables found to block late-stage breast-cancer cell growth
6. JCI table of contents, 2 August, 2004
7. When male fish hum, females swim in, thanks to hormones, adaptable hearing
8. JCI table of contents, 1 July 2004
9. Search and destroy protein turns tables on HIV
10. JCI table of contents, 15 June 2004
11. JCI table of contents, 1 June 2004

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI table contents August

(Date:5/18/2013)... MD (May 19, 2013) The AGA Research Foundation ... and Damian Augustyn Award in Digestive Cancer, which will ... of Medicine at the University of Pennsylvania, Philadelphia, as ... in pancreas development, regeneration and cancer progression. , "The ... in honor of two distinguished clinicians and AGA Legacy ...
(Date:5/18/2013)... (May 18, 2013) Research presented at Digestive ... digestive health through diet and lifestyle. , ... by reduced muscle strength, fatigue and poor quality ... patients are in remission. A randomized, double blind, ... vitamin D supplementation corresponded to significant relief of ...
(Date:5/17/2013)... AGA Research Foundation announced a new grant that intends ... microbiota, one of today,s most exciting areas of science, ... Research Awards Panel selected Andrew T. Chan, MD, MPH ... Medical School, Boston, as the 2013 AGA-Elsevier Gut Microbiome ... of funding, commencing in July 2013, to test the ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New gut microbiome research to explore red meat -- colorectal cancer pathway 2
(Date:5/21/2013)... , May 21, 2013 ... Dialysis and Transplant Association) is the biggest congress in ... replacement therapy. Nearly 10,000 participants are in ... the latest research findings. New pioneering studies have been ... "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA ...
(Date:5/21/2013)... , May 21, 2013 ... Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products and Services ... Tests) - U.S. Industry Analysis, Size, Share, Growth, Trends and Forecast, ... in 2011 and is expected to grow at a ... an estimated value of USD 4.7 billion in 2018. ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... 2013 Revolutionary Science, the manufacturer of ... announced today that they have expanded their colony counter ... IncuCount, IntelliCount, InCount and ImpressCount. These affordable colony ... useful in food microbiology and pharmaceutical manufacturing. , The ... A bright white enclosure with jet black accents ...
Breaking Biology Technology:ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2
Cached News: